Genus PLC GNS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GNS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- GBX 1,752.00
- Day Range
- GBX 1,740.00–1,798.00
- 52-Week Range
- GBX 1,478.00–2,798.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 115.95 Bil
- Volume/Avg
- 198,583 / 126,855
Key Statistics
- Price/Earnings (Normalized)
- 28.53
- Price/Sales
- 1.68
- Dividend Yield (Trailing)
- 1.83%
- Dividend Yield (Forward)
- 1.83%
- Total Yield
- 1.83%
Company Profile
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency. Genus also offers embryos through its subsidiary IVB.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 3,536
- Website
- https://www.genusplc.com
Comparables
Valuation
|
Metric
|
GNS
|
CVSG
|
001201
|
|---|---|---|---|
Price/Earnings (Normalized) | 28.53 | 13.74 | — |
Price/Book Value | 2.02 | 2.54 | 1.49 |
Price/Sales | 1.68 | 1.05 | 2.92 |
Price/Cash Flow | — | 7.13 | — |
Price/Earnings
GNS
CVSG
001201
Financial Strength
|
Metric
|
GNS
|
CVSG
|
001201
|
|---|---|---|---|
Quick Ratio | 1.30 | 0.88 | 0.35 |
Current Ratio | 2.15 | 1.15 | 0.69 |
Interest Coverage | — | 6.54 | −5.77 |
Quick Ratio
GNS
CVSG
001201
Profitability
|
Metric
|
GNS
|
CVSG
|
001201
|
|---|---|---|---|
Return on Assets (Normalized) | — | 11.55% | −7.87% |
Return on Equity (Normalized) | — | 26.87% | −13.26% |
Return on Invested Capital (Normalized) | — | 15.77% | −7.97% |
Return on Assets
GNS
CVSG
001201
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dhmvbpybq | Mcdg | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mcqjcdbw | Hvbjtrp | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qpfkyftb | Swtpvv | $98.1 Bil | |
MRNA
| Moderna Inc | Sstpqplnw | Gkdwp | $39.7 Bil | |
ARGX
| argenx SE ADR | Bygqnyxg | Lvdl | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Vrhmqclx | Dkbk | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zccbzdz | Ywdhyf | $18.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Brczbft | Jxzzs | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vcclphbpc | Csnvx | $12.5 Bil | |
INCY
| Incyte Corp | Jlzdtfnj | Fjpcnx | $11.8 Bil |